Skip to main content
S&P 5007,636.31+1.12%DOW51,808.37+0.67%NASDAQ26,393.18+1.60%BTC$76,547.00+0.91%ETH$2,453.08+2.03%GOLD$4,390.70+0.07%OIL$101.91-0.51%
Smart Investors Daily
Beyond Air, Inc. logo

NASDAQ · XAIR

Beyond Air, Inc.

Healthcare · Medical - Devices

$3.08

Up+$0.09 (+2.92%)

Updated Sep 17, 2026, 5:10 PM

SID Score

5.0/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
5.6M
P/E ratio
-0.13
Dividend yield
0.00%
52-week range
$0.33 – $9.28
Volume
20.12K
Avg. volume
537.56K

Price performance

XAIR price history

1M range · 20 trading sessions · Daily adjusted prices

XAIR closed at $3.08 after 20 trading sessions, down 40.88% for the selected period.

Last close
$3.08
Period change
-40.88%
Period low
$3.07
Period high
$5.70
Daily close
View OHLC price history
XAIR OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Sep 16, 2026$3.13$3.1861$3.06$3.0820.12K
Sep 15, 2026$3.16$3.2027$3.08$3.1320.49K
Sep 14, 2026$3.24$3.28$3.10$3.1435.3K
Sep 11, 2026$3.09$3.29$3.07$3.2064.46K
Sep 10, 2026$3.16$3.1925$3.063$3.0744.45K
Sep 9, 2026$3.40$3.43$3.18$3.1854.98K
Sep 8, 2026$3.51$3.58$3.3235$3.3883.96K
Sep 4, 2026$3.55$3.6401$3.50$3.5348.54K
Sep 3, 2026$3.60$3.69$3.52$3.5974.78K
Sep 2, 2026$3.61$3.95$3.61$3.62142.75K
Sep 1, 2026$3.78$3.94$3.60$3.66265.99K
Aug 31, 2026$4.52$4.52$3.85$3.978.75M
Aug 28, 2026$4.39$4.73$4.25$4.48313.82K
Aug 27, 2026$4.94$5.70$4.6005$5.701.12M
Aug 26, 2026$4.96$4.97$4.7001$4.9714.64K
Aug 25, 2026$4.68$5.0667$4.3748$4.98289.66K
Aug 24, 2026$5.12$5.4899$4.85$4.9122.01K
Aug 21, 2026$5.30$5.31$4.88$5.0423.91K
Aug 20, 2026$5.12$5.5521$5.01$5.1630.85K
Aug 19, 2026$5.95$5.95$5.09$5.2172.76K

Latest XAIR news

The latest Smart Investors Daily articles mentioning XAIR.

Stock researchCompany · Overview

XAIR research

Overview

Company profile and research snapshot.

Company profile

Beyond Air Inc is a commercial-stage medical device and biopharmaceutical company that develops a Nitric Oxide (NO) Generator and Delivery System that uses NO generated from ambient air and delivers precise amounts of NO to the lungs for the potential treatment of respiratory and other diseases. The firm is applying its therapeutic expertise to develop treatments for pulmonary hypertension, in addition to treatments for lower respiratory tract infections.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
Buy
Average target
$1.00
Implied upside
—
Analysts
11
XAIR recent ratings
DateFirmRatingTarget
Sep 1, 2026Lake StreetBuy—
Mar 27, 2026D. Boral CapitalBuy—
Mar 18, 2026D. Boral CapitalBuy—
Mar 10, 2026D. Boral CapitalBuy—
Jan 21, 2026D. Boral CapitalBuy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Sep 2, 2026

Beyond Air to Participate in the 2026 Cantor Global Healthcare Conference

GARDEN CITY, N.Y., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR), a commercial-stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve patients' lives, today announced that its management team will participate in the 2026 Cantor Global Healthcare Conference, which is being held at the Waldorf Astoria New York, New York on September 9-11, 2026. Fireside Chat Details:Date: Thursday, September 10thTime: 3:55 PM EDT Webc

Yahoo · Aug 31, 2026

Beyond Air® Receives FDA Breakthrough Device Designation for LungFit® GO to Treat Nontuberculous Mycobacterial Pulmonary Disease (NTM-PD)

GARDEN CITY, N.Y., Aug. 31, 2026 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) ("Beyond Air" or the "Company"), a commercial-stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve patients' lives, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation to LungFit GO for the treatment of nontuberculous mycobacterial pulmonary disease (NTM-PD). The Breakthrough Device Designation

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By